Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Feb;58(2):79-84.
doi: 10.1136/ard.58.2.79.

Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis

Affiliations
Clinical Trial

Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis

C J Haagsma et al. Ann Rheum Dis. 1999 Feb.

Abstract

Objective: To study the influence of sulphasalazine (SSZ), methotrexate (MTX), and the combination (COMBI) of both on plasma homocysteine and to study the relation between plasma homocysteine and their clinical effects.

Methods: 105 patients with early rheumatoid arthritis (RA) were randomised between SSZ (2-3 g/day), MTX (7.5-15 mg/week), and the COMBI (same dose range) and evaluated double blindly during 52 weeks. Plasma homocysteine, serum folate concentrations, and vitamin B12 were measured. The influence of the C677T mutation of the enzyme methyl-enetetrahydrofolatereductase (MTHFR) gene was analysed.

Results: A slight trend towards increased efficacy and an increased occurrence of minor gastrointestinal toxicity was present in the COMBI group, no differences existed clinically between SSZ and MTX. Only a slight and temporary increase in plasma homocysteine was found in the SSZ group, in contrast with the persistent rise in the MTX group and the even greater increase in the COMBI patients. Patients homozygous for the mutation in the MTHFR gene had significantly higher baseline homocysteine, heterozygous MTHFR genotype induced a significantly higher plasma homoeysteine at week 52 compared with no mutation. No correlation was found between clinical efficacy variables and homocysteine. Patients with gastrointestinal toxicity had a significantly greater increase in homocysteine.

Conclusion: A persistent increase in plasma homocysteine concentrations was observed in patients treated with MTX alone and more pronounced in combination with SSZ, in contrast with SSZ alone. An increase in plasma homocysteine is related to the C677T mutation in MTHFR. A relation in the change in homocysteine concentrations with (gastrointestinal) toxicity was found, no relation with clinical efficacy existed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Folate metabolism. DHF: dihydrofolate, THF: tetrahydrofolate, 5',10-'CH2-THF: methylene-THF, 5'-CH3-THF: methyl-THF, MTHFR: methylenetetrahydrofolate reductase, MS: methionine synthase, BHMT: betaine-homocysteine methyl transferase, B12: vitamin B12.
Figure 2
Figure 2
Plasma homocysteine compared with time. SSZ: sulphasalazine, MTX: methotrexate, COMBI : SSZ + MTX.

Similar articles

Cited by

References

    1. Gastroenterology. 1973 Apr;64(4):517-25 - PubMed
    1. J Rheumatol. 1998 Mar;25(3):441-6 - PubMed
    1. J Clin Invest. 1985 Sep;76(3):907-12 - PubMed
    1. Scand J Rheumatol. 1985;14(3):265-70 - PubMed
    1. Arthritis Rheum. 1988 Jul;31(7):906-8 - PubMed

Publication types

MeSH terms